Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Celgene, Concert in $300M+ Deuterium Drug Collaboration

Celgene will use Concert Pharmaceuticals’ deuterated chemical entity (DCE) Platform® technology to create new deuterium-modified small molecule compounds targeting cancer and inflammation, in a collaboration that could net the latter more than $300 million. In

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Celgene will use Concert Pharmaceuticals’ deuterated chemical entity (DCE) Platform® technology to create new deuterium-modified small molecule compounds targeting cancer and inflammation, in a collaboration that could net the latter more than $300 million.

In return for using the DCE technology, Celgene agreed to give Concert an up-front payment. And if Celgene exercises its options and agrees to develop DCE-based drugs, Concert will be eligible for more than $300 million in payments tied to development, regulatory, and sales milestones for each program selected for development by Celgene. In addition, Concert will receive tiered royalties on any product sales for each of the programs advanced by Celgene.

Founded in 2006, Concert seeks to apply its DCE technology to approved drugs and other agents with known human pharmacological activity, with the goal of creating new medicines that the company says have potential for enhanced efficacy, better tolerability and improved safety. Deuterium is an isotope of hydrogen with twice its atomic mass, allowing for stronger bonding with carbon, yet according to the company it has yet to be systematically studied for its safety and efficacy in medicines.

“Celgene’s deep experience developing clinically meaningful therapies, and their global commitment to patients across multiple therapeutic areas, make them an ideal partner,” Roger Tung, Ph.D., Concert’s president and CEO, said in a statement. “We look forward to working with Celgene to evaluate the potential benefits of deuterium-modification for a number of programs emerging in our pipeline.”

Concert’s pipeline includes compounds for a variety of disorders. Furthest along is CTP-499, a diabetic kidney disease drug candidate now in Phase II development.

Next furthest along in the pipeline is AVP-786, a Phase I neurologic disorders drug candidate being developed with Avanir Pharmaceuticals under an undisclosed but reportedly $200 million-plus collaboration announced last year. Also in Concert’s pipeline are CTP-354 for spasticity and neuropathic pain; C-10068 for epilepsy and depression; D-Ivacaftor for cystic fibrosis and COPD; and D-Praziquantel, now in a research phase for schistosomiasis.

The collaborations with Avanir and now Celgene mark two of three partnerships Concert has entered into in the past 15 months. The other collaboration, announced February 26, combines Concert with Jazz Pharmaceuticals in the development of narcolepsy drug C-10323, now in a preclinical phase, also for an undisclosed sum but including what several news accounts reported as $120 million in milestone and royalty payments.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What to expect from your doctor

After getting detailed information about the symptoms and your family's medical history, your healthcare professional may order tests to help with diagnosis and plan treatment. Your healthcare professional also may ask questions, such as: What symptoms are you or your child having? When did the symptoms start? Does anything make the symptoms better or worse? Has anyone in your family ever had cystic fibrosis? Has growth been average and weight been stable? Cystic fibrosis. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/cystic-fibrosis. Accessed Aug. 8, 2024. Bronchiectasis. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/bronchiectasis. Accessed Aug. 8, 2024. FAQs: Cystic fibrosis: Prenatal screening and diagnosis. American College of Obstetricians and Gynecologists. https://www.acog.org/womens-health/faqs/cystic-fibrosis-prenatal-screening-and-diagnosis. Accessed Aug. 8, 2024. Ferri FF. Cystic fibrosis. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Kliegman RM, et al., eds. Cystic fibrosis. In: Nelson Textbook of Pediatrics. 22nd ed. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Kellerman RD, et al. Cystic fibrosis. In: Conn's Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Lockwood CJ, et al., eds. Respiratory diseases in pregnancy. In: Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. 9th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Aug. 8, 2024. Ong T, et al. Cystic fibrosis: A review. JAMA. 2023; doi:10.1001/jama.2023.8120. Rubin R. Tackling the misconception that cystic fibrosis is a "white people's disease." JAMA. 2021; doi:10.1001/jama.2021.5086. Care centers. Cystic Fibrosis Foundation. https://www.cff.org/managing-cf/care-centers. Accessed Aug. 8, 2024. Trikafta (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.trikafta.com/. Accessed Aug. 8, 2024. Symdeko (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.symdeko.com/. Accessed Aug. 8, 2024. Orkambi (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.orkambi.com/. Accessed Aug. 8, 2024. Kalydeco (prescribing information). Vertex Pharmaceuticals Inc.; 2023. https://www.kalydeco.com/. Accessed Aug. 8, 2024. Pilewski JM. Update on lung transplantation for cystic fibrosis. Clinics in Chest Medicine. 2022; doi:10.1016/j.ccm.2022.07.002. Fridell JA, et al. Pancreas transplantation for cystic fibrosis: A frequently missed opportunity. Clinical Transplantation. 2021; doi:10.1111/ctr.14371. Wadsworth LE, et al. Non-invasive ventilation is associated with long-term improvements in lung function and gas exchange in cystic fibrosis adults with hypercapnic respiratory failure. Journal of Cystic Fibrosis. 2021; doi:10.1016/j.jcf.2021.05.011. Allscripts EPSi. Mayo Clinic. Medical review (expert opinion). Mayo Clinic. Oct. 18, 2024.

Source: www.mayoclinic.org ↗
02What is cystic fibrosis? A Mayo Clinic expert explains

Learn more from pulmonologist Sarah Chalmers, M.D. Cystic fibrosis (CF) is a condition passed down in families that causes damage to the lungs, digestive system and other organs in the body. CF affects the cells that make mucus, sweat and digestive juices. These fluids, also called secretions, are usually thin and slippery to protect the body's internal tubes and ducts and make them smooth pathways. But in people with CF, a changed gene causes the secretions to become sticky and thick. The secretions plug up pathways, especially in the lungs and pancreas. CF gets worse over time and needs daily care, but people with CF usually can attend school and work. They often have a better quality of life than people with CF had in past decades. Better screening and treatments mean that people with CF now may live into their mid- to late 50s or longer, and some are being diagnosed later in life.

Source: www.mayoclinic.org ↗
03What Is Cystic Fibrosis?

Cystic fibrosis (CF) is a genetic disorder, which means you get it from your parents at birth. It affects your lungs, pancreas, and other organs. CF changes the way chloride (salt) moves through the cells of your body. This causes the mucus (which should be thin and slippery) in various organs to become thick and sticky. Over time, this thick mucus builds up inside your airways, making it hard to breathe. The mucus traps germs and leads to infections and inflammation. It can also cause severe, long-term damage to the lungs and lead to respiratory failure (inability to breathe normally) and death. In the pancreas, the thick mucus caused by CF prevents the release of digestive enzymes when you eat. This leads to malnutrition and poor growth. CF can also cause liver disease, reproductive problems, and cystic fibrosis-related diabetes (CFRD). More than 40,000 people in the U.S. live with CF. Doctors diagnose about 1,000 new cases each year. Today, more than half of the CF population is aged 18 or older, and new treatments have expanded the life expectancy by decades.

Source: www.webmd.com ↗
04What is a sweat test?

A sweat test measures the amount of chloride in your sweat . Chloride is a type of electrolyte . Electrolytes are electrically charged minerals  that help control the amount of fluids and the balance of acids and bases (pH balance) in your body. Chloride and sodium form the salt found in your sweat.

Source: medlineplus.gov ↗
05What Types of Drug Interactions Can Happen?

Your body uses special enzymes called CYP450 to break down certain medicines. When you have long-term illness, your body may produce more or less of these enzymes, which can change how some medicines work. Some medicines and foods may affect the levels of these enzymes, which could impact how Alyftrek works in your body. Avoid CYP3A Inducers: Some medicines called CYP3A inducers (e.g. carbamazepine or rifampin ) can lower the amount of Alyftrek in your body, making it less effective. Be Cautious with CYP3A inhibitors: CYP3A inhibitors (e.g. erythromycin or itraconazole ) can increase the levels of Alyftrek in the body, which may raise the risk of side effects. If you are taking one of these medicines, your health care provider may adjust your Alyftrek dose. Avoid grapefruit products: Grapefruit and grapefruit juice can also increase the amount of Alyftrek in the body, so it is best to avoid them while on this medicine. Alyftrek can also affect how other medicines work in your body. P-gp and BCRP substrates: Alyftrek may increase the levels of certain medicines that rely on P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein) in the body. This could lead to stronger effects or more side effects from those medicines. Your health care provider may monitor you more closely if you are taking one of these medicines. CYP2C9 substrates (e.g., warfarin): Alyftrek may interfere with CYP2C9 substrates, such as warfarin , a blood thinner. If you take warfarin, your doctor may need to check your blood clotting levels more often. Always tell your health care provider about any prescription or over-the-counter (OTC) medicines, vitamins/minerals, herbal products, and other supplements you are using or have recently taken. This will help make sure your medicines work well together.

Source: www.webmd.com ↗
Research context

Read sources and limitations before applying a claim.

Research and Statistics: Who Has Cystic Fibrosis?

About 40,000 people are living with cystic fibrosis in the United States, and there are approximately 105,000 people with CF worldwide. (3) More than 75 percent of people with the disease are diagnosed by age 2, and more than half of all people living with cystic fibrosis are 18 or older. CF occurs predominantly in white populations, at a rate of 1 in 2,500 births. Between 2 and 5 percent of white people are carriers of the CFTR gene variant but have no overt clinical signs of disease. The disease is less common among African Americans, occurring at the much lower frequency of approximately 1 out of 17,000 births. (15) CF gene variants are most prevalent in persons of northern and central European ancestries or of Ashkenazi Jewish descent. They are rarely found in Native Americans, Asians, or native Africans. (16) CF is equally common among men and women, but women patients fare significantly worse than male patients with the disease. The median survival age for female CF patients is about three years younger than it is for men, but the reasons for the poorer survival rates among women are not completely understood. (17)

Source: everydayhealth.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →